Research
Hormonal
Clofibric acid (1.6g/day) prevents the increase of triglyceride levels in newly diagnosed NIDDM patients but has no additional effect on glucose control, cholesterol, or cardiovascular outcomes compared to placebo.
Clofibric acid at 1.6g/day effectively prevents triglyceride increases in newly diagnosed diabetics but does not improve blood sugar or cholesterol. It should be used selectively for patients with high triglycerides, not as a general diabetes treatment.
GoodQualifiesHIGH confidence
Clofibric acid only prevented the increase of triglyceride levels... Clofibric acid had no additional effect on the course of diabetes... As shown in the World Health Organization Study, clofibric acid predominantly acts on triglycerides.
Why this rating
Double-blind, placebo-controlled subset of the main trial.
Source
Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM
M Hanefeld et al. · Diabetes Care · 1991
DOI 10.2337/diacare.14.4.308
rct · n=1139Cited 168×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →